EnovisENOV
ENOV
About: Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Employees: 7,367
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
243% more call options, than puts
Call options by funds: $63.9M | Put options by funds: $18.6M
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
45% more repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 83
20% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 40
4.13% more ownership
Funds ownership: 110.53% [Q4 2024] → 114.66% (+4.13%) [Q1 2025]
1% more funds holding
Funds holding: 286 [Q4 2024] → 289 (+3) [Q1 2025]
8% less capital invested
Capital invested by funds: $2.71B [Q4 2024] → $2.49B (-$217M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
72%
upside
Avg. target
$61
90%
upside
High target
$70
119%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Caitlin Cronin | 119%upside $70 | Buy Maintained | 14 May 2025 |
JMP Securities David Turkaly | 72%upside $55 | Market Outperform Maintained | 9 May 2025 |
Needham Mike Matson | 79%upside $57 | Buy Maintained | 9 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Neutral
GlobeNewsWire
2 weeks ago
Orthopedic Braces & Supports Market Focused Insights 2025-2030, with Key Vendor Profiles for BREG, Bauerfeind, DeRoyals, Enovis, Ottobock, Ossur and Tynor
Key developments include Icarus Medical Innovation's Adonis Knee brace with joint-distraction technology and Enovis DJO, LLC's DonJoy ROAM knee brace. The knee braces segment holds over 35% market share, fueled by prevalent knee injuries. Hinged braces show the highest growth at 5.31%. Key developments include Icarus Medical Innovation's Adonis Knee brace with joint-distraction technology and Enovis DJO, LLC's DonJoy ROAM knee brace. The knee braces segment holds over 35% market share, fueled by prevalent knee injuries. Hinged braces show the highest growth at 5.31%.
Neutral
Seeking Alpha
1 month ago
Enovis Corporation (ENOV) Q1 2025 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matthew Trerotola - Chair and Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Dane Reinhardt - Baird Danielle Antalffy - UBS Russell Yuen - William Blair Young Li - Jefferies Operator Hello, everyone, and welcome to the Enovis Corporation Q1 2025 Results Call. My name is Ezra, and I will be your coordinator today.
Positive
Zacks Investment Research
1 month ago
Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates
Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Enovis Announces First Quarter 2025 Results
Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12 th , 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Neutral
GlobeNewsWire
1 month ago
Enovis to Host First Quarter 2025 Results Conference Call on May 8th
Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com.
Neutral
GlobeNewsWire
2 months ago
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer
WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million.
Neutral
GlobeNewsWire
2 months ago
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year's American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking place March 27-30.
Neutral
GlobeNewsWire
3 months ago
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Positive
Seeking Alpha
3 months ago
Enovis Continues To Languish Despite Decent Financial Results
Enovis shares have continued to languish despite on-target financial performance, with Q4'24 results meeting expectations and featuring double-digit growth in its Reconstructive business. Enovis' Recon business outperformed its larger rivals in Q4, with double-digit growth in global hips and knees and double-digit growth in U.S. knees as well. Uncertainty from an unexpected CEO transition and potential 2025 tariffs only add to market hesitation.
Charts implemented using Lightweight Charts™